TTRNA-DC vaccines

Developed for: diffuse intrinsic pontine glioma · high grade astrocytic tumor · medulloblastoma non-WNT/non-SHH group 3 · medulloblastoma non-WNT/non-SHH group 4
Investigated by: University of Florida · Accelerate Brain Cancer Cure · Children's National Research Institute · Lyla Nsouli Foundation · Moffitt Clinical Research Network (MCRN) · National Cancer Institute (NCI)
+2 more
· National Institutes of Health (NIH) · National Pediatric Cancer Foundation

201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1	NCT06514898	May 2025 → Sep 2027 expected	medulloblastoma non-WNT/non-SHH group 3, medulloblastoma non-WNT/non-SHH group 4	University of Florida	Recruiting	No outcome recorded
Phase 1	NCT03334305	Aug 2018 → Mar 2025	high grade astrocytic tumor	University of Florida	Terminated	No outcome recorded Stop: Enrollment
Phase 1	NCT03396575	Jul 2018 → Mar 2025	diffuse intrinsic pontine glioma	University of Florida	Terminated	No outcome recorded Stop: Enrollment

Every value below carries the sentence it was read from. 3 sources stand behind the page.

Field	Value	Cited text
Known as	TTRNA-DC vaccines	ClinicalTrials.gov intervention name — accepted as the source's own label NCT03396575 ↗ 2 NCT03334305 ↗ NCT06514898 ↗
Modality	Vaccine	“DC vaccines” NCT03334305 ↗
Route	Other	“given intradermal” NCT06514898 ↗